The Time Has Come: Surgical Administration of Durable Medical Therapy...

Actions Panel

Ticket sales end soon

The Time Has Come: Surgical Administration of Durable Medical Therapy...

This program is intended for AAO attendees only.

When and where

Date and time

Location

Hilton Chicago Downtown 720 S Michigan Ave Continental A; New Lobby Level Chicago, IL 60605

Map and directions

How to get there

About this event

Activity Chair

Arshad M. Khanani, MD, MA, FASRS

Managing Partner

Director of Clinical Research

Director of Fellowship

Sierra Eye Associates

Clinical Associate Professor

University of Nevada

Reno, NV

Faculty

Sara J. Haug, MD, PhD

Partner, Southwest Eye Consultants, Durango, CO

Director of Clinical Research

Southwest Retina Research Center

Durango, CO

Dante J. Pieramici, MD

Director, California Retina Research Foundation

Partner, California Retina Consultants

Santa Barbara, CA

Lejla Vajzovic, MD, FASRS

Director, Duke Surgical Vitreoretinal Fellowship Program

Director, Duke Center for Artificial and Regenerative Vision

Co-Director, Duke Pediatric Retina and Optic Nerve Center

Director, Duke Eye Center Continuing Medical Education

Director, Duke fAVS and AVS Courses

Associate Professor of Ophthalmology

Adult and Pediatric Vitreoretinal Surgery and Diseases

Duke University Eye Center

Durham, NC

Overview

Suboptimal outcomes in patients with retinal vascular diseases receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapy have been associated with loss of adherence due to treatment burden. However, novel delivery devices and gene therapies that reduce the need for frequent dosing have now been developed. The Port Delivery System (PDS) with ranibizumab was recently FDA-approved for the management of patients with neovascular age-related macular degeneration (nAMD), while gene therapies are currently being evaluated in ongoing clinical studies. To achieve optimal efficacy and safety outcomes, these novel delivery modalities require unique surgical approaches for their implication into clinical practice. In this CME activity, experts in the field will discuss the risks and benefits of intravitreal versus surgical administration of agents used in the management of patients with retinal vascular diseases, evaluate new and emerging surgically delivered therapies that can enhance outcomes by reducing treatment burden, and provide best practices that can reduce the potential for complications when utilizing the PDS with ranibizumab or subretinal gene therapy in the management of patients with nAMD.

Agenda

6:00 PM

Registration and Dinner

6:30 PM

Introduction and Pretest

Arshad M. Khanani, MD, MA

6:35 PM

Extending Treatment Intervals in Retinal Vascular Diseases: Are We There Yet?

Sara J. Haug, MD, PhD

6:50 PM

Deep Dive Into the PDS

Dante J. Pieramici, MD

7:15 PM

RGX314: Assessing New Evidence

Lejla Vajzovic, MD

7:30 PM

Case Presentations

Arshad M. Khanani, MD, MA

7:45 PM

Posttest and Question & Answer

8:00 PM

Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Compare the risks and benefits of intravitreal versus surgical administration of agents used in the management of retinal vascular diseases.

  • Apply current evidence to practice regarding new and emerging surgically delivered therapies that can enhance outcomes in patients with retinal vascular diseases by reducing treatment burden.

  • Incorporate best practices that can reduce the potential for complications when using the PDS or subretinal gene therapy for nAMD.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal vascular diseases.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

This activity is not affiliated with the official program of AAO 2022.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity.

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.

Ticket sales end soon